Cargando…
S-1 and Cisplatin With or Without Nimotuzumab for Patients With Untreated Unresectable or Metastatic Gastric Cancer: A Randomized, Open-Label Phase 2 Trial
This open-label, randomized phase II trial was performed to compare the efficacy and safety of nimotuzumab plus S-1 and cisplatin (NCS) versus S-1 and cisplatin (CS) alone in patients with untreated unresectable or metastatic gastric cancer in the first-line setting. Eligible participants were rando...
Autores principales: | Du, Feng, Zheng, Zhaoxu, Shi, SuSheng, Jiang, Zhichao, Qu, Tao, Yuan, Xinhua, Sun, Yongkun, Song, Yan, Yang, Lin, Zhao, Jiuda, Wang, Jinwan, Chi, Yihebali |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4616475/ https://www.ncbi.nlm.nih.gov/pubmed/26061330 http://dx.doi.org/10.1097/MD.0000000000000958 |
Ejemplares similares
-
The efficacy and safety of neoadjuvant nimotuzumab for gastric cancer: A meta-analysis of randomized controlled studies
por: Cao, Bin, et al.
Publicado: (2021) -
Hepatocellular carcinoma treated with anti-epidermal growth factor receptor antibody nimotuzumab: A case report
por: Song, Peng, et al.
Publicado: (2017) -
Induction chemotherapy with sequential nimotuzumab plus concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma: A retrospective real-world study
por: Jiang, Danxian, et al.
Publicado: (2023) -
Target Therapy of Unresectable or Metastatic Dermatofibrosarcoma Protuberans With Imatinib Mesylate: An Analysis on 22 Chinese Patients
por: Wang, Chunmeng, et al.
Publicado: (2015) -
Durable response to immunotherapy plus chemotherapy in a patient with untreated, brain-metastatic, EGFR exon 20 insertion mutation lung adenocarcinoma: A case report
por: Nong, Jingying, et al.
Publicado: (2021)